|
業務類別
|
Biotechnology |
|
業務概覽
|
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States. |
| 公司地址
| 300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000 |
| 電話號碼
| +61 294724101 |
| 傳真號碼
| +61 294760388 |
| 公司網頁
| https://www.kaziatherapeutics.com |
| 員工數量
| 6 |
| Dr. John E. Friend, II,M.D. |
Chief Executive Officer |
澳元 825.00K |
07/11/2025 |
| Mr. Jeffrey Bonacorda |
Vice President, Finance and Controller |
-- |
07/11/2025 |
| Ms. Elissa Hansen |
Company Secretary |
美元 2.27K |
07/11/2025 |
|
|
| Mr. Bryce D. Carmine |
Non-Executive Chairman of the Board |
07/11/2025 |
| Mr. Robert F. Apple |
Independent Director |
07/11/2025 |
| Mr. Steven Coffey |
Independent Director |
07/11/2025 |
| Ms. Ebru Davidson |
Independent Director |
07/11/2025 |
|
|
|
|
